Cureus | A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2

A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2


Abstract

ARRY-380 is a selective, oral HER2 inhibitor with satisfactory PK, and good predicted target coverage. It is well tolerated with low incidence and severity of diarrhea, rash, fatigue.
Poster
non-peer-reviewed

A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2


Author Information


PDF Share